中国P站

Organ preservation; Ischemia-reperfusion injury; Cold storage; Machine perfusion; Hypothermic machine perfusion; Normothermic machine perfusion; Ex vivo organ preservation; Organ viability; Extended donor criteria; Graft survival; Organ transplantation; Organ preservation technologies; Ischemic injury; Transplant success; Cold ischemic time; Organ recovery; Preservation solutions; Perfusion systems; Preservation strategies.

Introduction

Organ transplantation remains one of the most successful therapeutic interventions for end-stage organ failure. However, one of the major limitations to the widespread success of organ transplantation is the inherent challenge of preserving organ function after procurement. The process of organ preservation aims to prevent damage from ischemia, a condition where the organ is deprived of blood flow, leading to cellular injury and impaired graft function post-transplantation. Traditional methods, such as cold storage, have made significant contributions in maintaining organ viability, but they come with limits in terms of ischemia-reperfusion injury, which compromises long-term graft function. In recent years, next-generation organ preservation techniques, particularly machine perfusion technologies, have emerged as a promising strategy to extend organ viability, minimize ischemic damage, and improve transplant outcomes. These advancements are poised to revolutionize transplant medicine by enhancing the success rates of both marginal and expanded criteria donor organs [1-5].

Description

Traditional cold storage involves cooling the harvested organ and preserving it in preservation solutions that slow metabolic processes and reduce cellular activity. However, this method is limited by the time constraint on organ viability (typically 4-12 hours, depending on the organ), after which ischemia-reperfusion injury can severely impair organ function. The process of ischemia-reperfusion injury occurs when an organ, once deprived of blood flow during preservation, is suddenly reperfused with oxygenated blood during transplantation, resulting in oxidative stress, inflammation, and cellular damage that can lead to graft dysfunction and rejection.

Machine perfusion technologies are a significant advancement, offering dynamic, active preservation of organs by maintaining perfusion to the organ throughout the preservation period. This includes hypothermic machine perfusion (HMP), which preserves organs at cold temperatures while continuously pumping a perfusion solution through the organ, and normothermic machine perfusion (NMP), which maintains organs at body temperature with oxygenated blood flow, simulating physiological conditions. These methods help maintain cellular metabolism, improve tissue oxygenation, and reduce the accumulation of toxic metabolites, all of which contribute to extending organ viability and improving graft function post-transplantation [6-10].

Discussion

The benefits of next-generation preservation techniques are evident in a number of key areas. Extended preservation times mean that organs can be transported over longer distances, increasing the likelihood of matching donors and recipients across wider geographical regions. This is especially important as transplant lists continue to grow and the gap between the supply of donor organs and the demand for transplants remains substantial. Additionally, machine perfusion has proven to be particularly beneficial for marginal organs—such as those from older donors, donors after circulatory death (DCD), or expanded criteria donors (ECD)—which traditionally have poorer outcomes due to higher levels of ischemia and cell damage. By improving the viability of these organs, machine perfusion allows for better graft function and, in many cases, offers an opportunity to safely use organs that would have otherwise been discarded.

Moreover, normothermic machine perfusion (NMP) has shown promise in reversing ischemic damage in certain organs, especially the liver and kidneys, by restoring metabolic activity and allowing for functional assessment before implantation. This real-time monitoring can help predict post-transplant organ performance, reducing the chances of delayed graft function or acute rejection episodes. The dynamic nature of machine perfusion also facilitates the use of advanced therapeutic agents, such as stem cells, gene therapy, and antioxidants, that can enhance organ recovery and repair during preservation.

Despite these promising developments, challenges remain. The cost and complexity of implementing machine perfusion technology at a large scale remain significant barriers, particularly in resource-limited healthcare settings. Additionally, while the benefits of extended preservation are clear, not all organs respond equally to machine perfusion, and more research is needed to determine the optimal protocols for different organ types and clinical scenarios. The long-term outcomes of machine-perfused organs also require further investigation, particularly with regard to potential effects on immune tolerance and rejection processes.

Furthermore, while next-generation preservation techniques have shown great promise in reducing ischemic injury, they do not fully address the risks of immune-mediated rejection, which remains a major challenge in organ transplantation. The integration of immunosuppressive therapies with advanced preservation methods will be necessary to ensure the success of transplanted organs over the long term.

Conclusion

Next-generation organ preservation technologies, including machine perfusion and ex vivo organ preservation, are reshaping the field of organ transplantation. By extending organ viability, reducing ischemic injury, and improving the overall success of transplant procedures, these advancements hold the potential to transform transplantation medicine. The ability to safely use marginal organs and to enhance the outcomes of high-risk grafts will expand the donor pool, reduce waitlist mortality, and increase the availability of organs for patients in need. However, the widespread implementation of these technologies requires addressing technical, economic, and clinical challenges, including the standardization of protocols, optimization of perfusion solutions, and long-term monitoring of graft outcomes. With continued research and innovation, next-generation organ preservation techniques are set to play a critical role in the future of transplantation, offering the promise of improved graft survival, enhanced transplant success, and better overall patient outcomes.

References

1. Khosravi N, Pishavar E, Baradaran B, Oroojalian F, Mokhtarzadeh A, et al. (2022) . J Control Release 348:706-722.

   , ,

2. Wu HH, Zhou Y, Tabata Y, Gao JQ (2019) . J Control Release 28: 102-113.

   , ,

3. Yan K, Zhang J, Yin W, Harding JN, Ma F et al. (2022) . IScience 4: 104822.

   , ,

4. Zhang W, Huang X (2022) . Mater Today Bio 1: 100377.

   , ,

5. Li Y, Wu H, Jiang X, Dong Y, Zheng J, et al. (2022) . Acta Pharm Sin B 12: 3215-3232.

   , ,

6. Ji B, Cai H, Yang Y, Peng F, Song M, et al. (2020) . Acta Biomater 111: 363-372.

   , ,

7. Wang M , Xin Y , Cao H , Li W , Hua Y, et al. (2021) . Biomater Sci 9:1088-1103.

   , ,

8. Xia Q, Zhang Y, Li Z, Hou X, Feng N, et al. (2019) . Acta Pharm Sin B 9: 675-689.

   , ,

9. Shin MJ, Park JY, Lee DH, Khang D (2021) . Int J Nanomedicine 16: 8485-8507.

   , ,

10. Vasanthan V, Hassanabad AF, Fedak PWM (2021) . JTCVS Open 24: 45-46.

    , ,